Ganliang Zhang

Title: Ganliang Zhang: Innovator in Bispecific Recombinant Proteins

Introduction

Ganliang Zhang is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of bispecific recombinant proteins. His innovative work aims to enhance cancer treatment through targeted therapies.

Latest Patents

Ganliang Zhang holds a patent for a bispecific recombinant protein and its applications. This protein comprises a high affinity tumor-targeting arm and a low affinity fusion protein that blocks the interaction of CD47 with SIRPα. The antibody associated with the high affinity tumor-targeting arm does not bind to CD47, ensuring that its binding affinity to the target antigen on tumor cells is at least six times greater than that of the corresponding low affinity fusion protein. This innovative approach includes nucleic acid molecules encoding the recombinant proteins, which can be utilized in the manufacture of medicaments for treating tumors. He has 1 patent to his name.

Career Highlights

Ganliang Zhang is affiliated with Shanghai JMT-Bio Technology Co., Ltd., where he continues to push the boundaries of biotechnological research. His work is instrumental in developing therapies that could potentially revolutionize cancer treatment.

Collaborations

He collaborates with notable colleagues, including Liping Song and Xiaotian Cui, who contribute to his research endeavors and innovations in the field.

Conclusion

Ganliang Zhang's contributions to the development of bispecific recombinant proteins highlight his role as a key innovator in biotechnology. His work promises to advance therapeutic options for cancer treatment, showcasing the potential of targeted therapies in modern medicine.